GENA COELHO: Open Payments
NPI 1467882787 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,586 in 69 payments from 19 companies in 2025. Trend: 2023 $1,349 · 2024 $1,845 · 2025 $1,586
Food & beverage: $1,586
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $412 |
| ARGENX US, INC. | 6 | $193 |
| Alexion Pharmaceuticals, Inc. | 8 | $153 |
| UCB, Inc. | 3 | $126 |
| Lilly USA, LLC | 5 | $95 |
| Axsome Therapeutics, Inc. | 3 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| SK Life Science, Inc. | 3 | $82 |
| Eisai Inc. | 3 | $63 |
| Celgene Corporation | 2 | $41 |
Products named: QULIPTA, VYVGART HYTRULO, ULTOMIRIS, Rystiggo, BOTOX, UBRELVY, Symbravo, REXULTI.
Industry payments across CT — which companies pay providers there.
